Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal toxicology shows wide therapeutic window Injection-site reactions reported anecdotally Known interactions Anticoagulants (theoretical, due to angiogenic activity unstudied) Contraindications Active malignancy (theoretical, due to angiogenic mechanism) Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A
Researchers may also be interested in BPC-157 Capsules, which provides the same compound in an alternative format
Some Australians unintentionally expose themselves to risk by selecting providers that do not fully meet TGA compliance or pharmaceutical-grade compounding standards
K.Cory-SlechtaD
US$ 20.17
US$ 26.38
US$ 23.69
US$ 27.12
US$ 24.67
US$ 26.70
US$ 20.68
US$ 25.37